Avoro Capital Advisors LLC portfolio
Managed by . 30 reported positions worth $10.2B as of 2026-03-31, filed with the SEC on 2026-05-15. Parsed from the filing itself, not a reseller.
Every position on this page is a snapshot of 2026-03-31. It was already 45 days old on 2026-05-15, the day it first became public. Today it is 134 days old.
That lag is the law, not a service level — Rule 13f-1 gives managers 45 days after quarter end to file, and no product can shorten it. A fund can have sold every share below before you read this sentence. Treat it as a record of what happened, never as a position you can follow.
Positions opened and closed
Against its 2025-12-31 filing. This is the part worth reading — the holdings table below is mostly years old.
| Ticker | Issuer | Value | Shares | % of book |
|---|---|---|---|---|
| 430 | TERNS PHARMACEUTICALS INC | $300.2M | 5,695,000 | 2.96% |
| CYTK | CYTOKINETICS INC | $219.7M | 3,333,333 | 2.16% |
| DAMORA THERAPEUTICS INC | DAMORA THERAPEUTICS INC | $98.0M | 3,783,000 | 0.97% |
| DFTX | DEFINIUM THERAPEUTICS INC | $94.5M | 5,000,000 | 0.93% |
| AVTX | AVALO THERAPEUTICS | $21.1M | 1,410,000 | 0.21% |
| Ticker | Issuer | Was worth | Shares | % of book |
|---|---|---|---|---|
| RNAGBP | AVIDITY BIOSCIENCES INC | $393.5M | 5,455,000 | 0.00% |
| XBI | SPDR SERIES TRUST - S&P BIOTECH | $256.1M | 2,100,000 | 0.00% |
| TERNS PHARMACEUTICALS IN | TERNS PHARMACEUTICALS INC | $175.7M | 4,350,000 | 0.00% |
| BRD1EUR | MIND MEDICINE (MINDMED) INC | $67.0M | 5,000,000 | 0.00% |
| PTCT 1.5 09/15/26 | PTC THERAPEUTICS INC | $52.0M | 685,000 | 0.00% |
| ORKA | ORUKA THERAPEUTICS INC | $40.4M | 1,333,340 | 0.00% |
| APGE | APOGEE THERAPEUTICS INC | $37.7M | 500,000 | 0.00% |
| INCY | INCYTE CORP | $13.3M | 135,000 | 0.00% |
| Ticker | Issuer | Value | Shares | % of book | Shares Δ |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | $730.2M | 1,000,000 | 7.19% | +1% |
| CELC | CELCUITY INC | $385.2M | 3,375,000 | 3.79% | +8% |
| XENE | XENON PHARMACEUTICALS INC | $336.0M | 5,777,777 | 3.31% | +7% |
| RVMD | REVOLUTION MEDICINES INC | $228.0M | 2,344,444 | 2.25% | +8% |
| OCUL | OCULAR THERAPEUTIX INC | $104.3M | 12,315,000 | 1.03% | +14% |
| Ticker | Issuer | Value | Shares | % of book | Shares Δ |
|---|---|---|---|---|---|
| MNKD | MANNKIND CORP | $5.4M | 2,200,000 | 0.05% | -50% |
| LXEO | LEXEO THERAPEUTICS INC | $10.8M | 1,875,000 | 0.11% | -43% |
| 260 | CENTESSA PHARMACEUTICALS PLC | $454.0M | 11,430,455 | 4.47% | -21% |
| SLNOEUR | SOLENO THERAPEUTICS INC | $77.0M | 2,300,000 | 0.76% | -21% |
| ALKS | ALKERMES PLC | $42.4M | 1,200,000 | 0.42% | -14% |
| UNIQURE NV | UNIQURE NV | $97.4M | 5,959,595 | 0.96% | -3% |
All reported holdings
| Ticker | Issuer | Value | Shares | % of book | Shares Δ |
|---|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS CORP | $1.6B | 2,630,000 | 15.36% | — |
| ASCENDIS PHARMA | ASCENDIS PHARMA | $1.2B | 5,062,500 | 11.41% | — |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $951.8M | 1,818,181 | 9.38% | — |
| KRYS | KRYSTAL BIOTECH INC | $746.3M | 2,888,888 | 7.35% | — |
| ARGX | ARGENX SE | $730.2M | 1,000,000 | 7.19% | — |
| ARWR | ARROWHEAD PHARMACEUTICALS INC | $670.9M | 10,699,999 | 6.61% | — |
| KYMR | KYMERA THERAPEUTICS INC | $622.6M | 7,474,747 | 6.13% | — |
| APLSUSD | APELLIS PHARMACEUTICALS INC | $491.7M | 12,222,222 | 4.84% | — |
| 260 | CENTESSA PHARMACEUTICALS PLC | $454.0M | 11,430,455 | 4.47% | — |
| CELC | CELCUITY INC | $385.2M | 3,375,000 | 3.79% | — |
| XENE | XENON PHARMACEUTICALS INC | $336.0M | 5,777,777 | 3.31% | — |
| GPCR | STRUCTURE THERAPEUTICS INC | $316.0M | 6,555,555 | 3.11% | — |
| 430 | TERNS PHARMACEUTICALS INC | $300.2M | 5,695,000 | 2.96% | — |
| VERA | VERA THERAPEUTICS INC | $236.9M | 5,888,888 | 2.33% | — |
| RVMD | REVOLUTION MEDICINES INC | $228.0M | 2,344,444 | 2.25% | — |
| CYTK | CYTOKINETICS INC | $219.7M | 3,333,333 | 2.16% | — |
| OCUL | OCULAR THERAPEUTIX INC | $104.3M | 12,315,000 | 1.03% | — |
| DAMORA THERAPEUTICS INC | DAMORA THERAPEUTICS INC | $98.0M | 3,783,000 | 0.97% | — |
| UNIQURE NV | UNIQURE NV | $97.4M | 5,959,595 | 0.96% | — |
| TSHA | TAYSHA GENE THERAPIES INC | $97.0M | 21,700,000 | 0.96% | — |
| DFTX | DEFINIUM THERAPEUTICS INC | $94.5M | 5,000,000 | 0.93% | — |
| SLNOEUR | SOLENO THERAPEUTICS INC | $77.0M | 2,300,000 | 0.76% | — |
| ALKS | ALKERMES PLC | $42.4M | 1,200,000 | 0.42% | — |
| SEPN | SEPTERNA INC | $32.1M | 1,337,500 | 0.32% | — |
| VRDN | VIRIDIAN THERAPEUTICS INC | $29.3M | 1,500,000 | 0.29% | — |
| GHRS | GH RESEARCH PLC | $25.3M | 1,800,000 | 0.25% | — |
| AVTX | AVALO THERAPEUTICS | $21.1M | 1,410,000 | 0.21% | — |
| LXEO | LEXEO THERAPEUTICS INC | $10.8M | 1,875,000 | 0.11% | — |
| WHWK | WHITEHAWK THERAPEUTICS INC | $9.8M | 2,849,402 | 0.10% | — |
| MNKD | MANNKIND CORP | $5.4M | 2,200,000 | 0.05% | — |
This manager also disclosed 2 options positions with a combined notional of $13.3M. Notional is not ownership, so it is excluded from the book value above rather than folded in to make the fund look bigger.
Rows are aggregated by CUSIP — a manager files the same security multiple times when different internal desks hold it. Tickers link to our own backtest of that asset where we cover it.
This page was built from one document: the 2026-03-31 Form 13F info table filed by Avoro Capital Advisors LLC (CIK 1633313, accession 0001104659-26-061754). Every other 13F site is reading the same file.
If anything here disagrees with it, the filing wins — and we would want to know. All 13F filings by this manager
A 13F is a long-only equity snapshot, and the holes in it are structural. Anyone selling you this data as "what the smart money is doing" is selling you one leg of a position:
- No short positions. None, ever. A fund shown here as bullish may be net short the same name through a book you cannot see.
- No cash, bonds, FX, commodities or non-US listings. A macro fund's entire thesis can be invisible.
- No intra-quarter round trips. Bought and sold inside the same quarter means it never appears at all.
- Options are notional, not ownership. We keep puts and calls in a separate bucket rather than adding their notional into a fund's book size, which is how a $2B fund gets reported as a $20B one.
- Confidential treatment. Managers can ask the SEC to withhold a position while they build it. Those holdings are legally absent from the filing, so a "new" position may be months old.
Tested and published by IndicatorEdge · backtest grid generated 2026-06-25 · base rates recomputed 2026-07-31 · how we test
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.